AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26093656 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine with reactivation of associative cue‐smoking memories
Number of subjects: 59
Study 26093656 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine without reactivation of associative cue‐smoking memories
Number of subjects: 59
Study 26093656 — intervention group
Group type: COMPARATOR
Intervention: Placebo with reactivation of associative cue‐smoking memories
Number of subjects: 59
Study 22697811 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance exercise programme
Number of subjects: 13
Study 22697811 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 13
Study 21709652 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diazepam
Number of subjects: 36
Study 21709652 — intervention group
Group type: COMPARATOR
Intervention: i.v. midazolam 1 mg
Number of subjects: 36
Study 21709652 — intervention group
Group type: COMPARATOR
Intervention: i.v. midazolam 3 mg
Number of subjects: 36
Study 18339606 — intervention group
Group type: EXPERIMENTAL
Intervention: myeloperoxidase (MPO)
Number of subjects: 1524
Study 18339606 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble CD40 ligand (sCD40L)
Number of subjects: 1524
Study 18339606 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO, BNP, and cTnI stratification
Number of subjects: 1524
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: VT cycle length < 350 ms
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF) < 25%
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: First VT cycle length
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying heart disease
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication of ICD implantation
Number of subjects: 158
Study 16895771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 158
Study 14711553 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, p.o. b.i.d.)
Number of subjects: 20
Study 11355560 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg single dose)
Number of subjects: 125
Study 11355560 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron‐folate supplements (36 mg iron and 5 mg folate daily)
Number of subjects: 125
Study 11355560 — intervention group
Group type: COMPARATOR
Intervention: Control (neither albendazole nor iron‐folate supplements)
Number of subjects: 125
Study 9146577 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal mucosal immunization (vaccine treated)
Number of subjects: 91
Study 9146577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 91
Study 8174435 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise (10 min pedaling at 85% predicted maximum heart rate)
Number of subjects: 6
Study 8174435 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 6
Study 3354431 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 15
Study 3354431 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 15
Study 3354431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31865505 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized circuit training (CT)
Number of subjects: 61
Study 31865505 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional strength training (ST)
Number of subjects: 61
Study 31865505 — intervention group
Group type: COMPARATOR
Intervention: Educational protocol (EP)
Number of subjects: 61
Study 29342272 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding decision-making about food and drink, dietary supplements, medications, alcohol, and recreational drugs.
Number of subjects: 20
Study 28126600 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine 60 μg/kg IV (R60)
Number of subjects: 0
Study 28126600 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine 80 μg/kg IV (R80)
Number of subjects: 0
Study 28126600 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine 100 μg/kg IV (R100)
Number of subjects: 0
Study 28126600 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine 40 μg/kg IV (R40)
Number of subjects: 0
Study 28126600 — intervention group
Group type: EXPERIMENTAL
Intervention: Acepromazine 0.1 mg/kg IV (ACE)
Number of subjects: 0
Study 28126600 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%, 5 mL IV)
Number of subjects: 0
Study 26150231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollator
Number of subjects: 15
Study 26150231 — intervention group
Group type: EXPERIMENTAL
Intervention: Draisine
Number of subjects: 15
Study 26150231 — intervention group
Group type: COMPARATOR
Intervention: Unaided walking
Number of subjects: 15
Study 23176568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle paclitaxel 300 mg/m² (NP300)
Number of subjects: 194
Study 23176568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle paclitaxel 220 mg/m² (NP220)
Number of subjects: 194
Study 23176568 — intervention group
Group type: COMPARATOR
Intervention: Cremophor paclitaxel 175 mg/m² (CP175)
Number of subjects: 194
Study 22000624 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of oxygenation, blood cultures, rapid initiation of antibiotic therapy <4 hours, appropriate selection of antibiotic therapy
Number of subjects: 2076
Study 22000624 — intervention group
Group type: COMPARATOR
Intervention: 0 to 2 processes of care performed
Number of subjects: 2076
Study 22000624 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 processes of care performed
Number of subjects: 2076
Study 22000624 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 processes of care performed
Number of subjects: 2076
Study 18434883 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 12/1.5 g/day after a loading dose of 4/0.5 g
Number of subjects: 40
Study 18434883 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 16/2 g/day after a loading dose of 4/0.5 g
Number of subjects: 40
Study 16256232 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART treatment
Number of subjects: 0
Study 16256232 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 12634635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous cervicocolpopexy with uterine conservation (Group A)
Number of subjects: 109
Study 12634635 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with sacrospinous colpopexy (Group B)
Number of subjects: 109
Study 11186163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer disease patients
Number of subjects: 32
Study 11186163 — intervention group
Group type: COMPARATOR
Intervention: Older adult controls
Number of subjects: 32
Study 8618367 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Compression-Decompression (ACD) CPR
Number of subjects: 1784
Study 8618367 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 1784
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 2.0 mg/kg
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 3.0 mg/kg
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 4.0 mg/kg
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 6.0 mg/kg
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 1.0 mg/kg (14C-labeled)
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin 0.5 to 6.0 mg/kg
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (all doses)
Number of subjects: 0
Study 1318678 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin (predicted effective doses)
Number of subjects: 0
Study 3871754 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS just above the patient's ability to perceive the stimuli
Number of subjects: 62
Study 3871754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (electrodes applied without electrical stimulation)
Number of subjects: 62
Study 30741801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (30 units in 500 mL of intravenous fluid)
Number of subjects: 160
Study 30741801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mL of intravenous fluid alone)
Number of subjects: 160
Study 29457516 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate-based products
Number of subjects: 20
Study 29457516 — intervention group
Group type: COMPARATOR
Intervention: Tested biscuit
Number of subjects: 20
Study 27724859 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.15 μg·kg−1·min−1) followed by immobility
Number of subjects: 16
Study 27724859 — intervention group
Group type: COMPARATOR
Intervention: Standardized movement intervention (head-trunk movement)
Number of subjects: 16
Study 24689056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA)
Number of subjects: 38
Study 24689056 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 38
Study 22157743 — intervention group
Group type: EXPERIMENTAL
Intervention: ASRA Checklist
Number of subjects: 25
Study 22157743 — intervention group
Group type: COMPARATOR
Intervention: No Checklist
Number of subjects: 25
Study 20499248 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 33
Study 20499248 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 33
Study 20499248 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 33
Study 17294149 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs
Number of subjects: 0
Study 17294149 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic drugs combined with psychotherapy
Number of subjects: 0
Study 17294149 — intervention group
Group type: COMPARATOR
Intervention: Polypharmacy
Number of subjects: 0
Study 16118079 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 courses of anthracycline-based chemotherapy (CT group)
Number of subjects: 1146
Study 16118079 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group)
Number of subjects: 1146
Study 12270028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg taken 4 hours before expected time of sex for 6 months
Number of subjects: 87
Study 10052020 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C capsule daily during weeks 4-5
Number of subjects: 9
Study 10052020 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule daily during weeks 1-3
Number of subjects: 9
Study 7577894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) in preloads
Number of subjects: 74
Study 7577894 — intervention group
Group type: EXPERIMENTAL
Intervention: Water in preloads
Number of subjects: 74
Study 7577894 — intervention group
Group type: COMPARATOR
Intervention: Fat in preloads
Number of subjects: 74
Study 7577894 — intervention group
Group type: COMPARATOR
Intervention: Rice and macaroni preloads
Number of subjects: 74
Study 2174464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus regimen of etoposide (VP‐16) and cisplatin (CDDP)
Number of subjects: 113
Study 2174464 — intervention group
Group type: COMPARATOR
Intervention: Infusion regimen of etoposide (VP‐16) and cisplatin (CDDP)
Number of subjects: 113
Study 2174464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus regimen
Number of subjects: 113
Study 2174464 — intervention group
Group type: COMPARATOR
Intervention: Infusion regimen
Number of subjects: 113
Study 6999637 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol treatment for 6 months
Number of subjects: 36
Study 6999637 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol combined with conservative surgery
Number of subjects: 36
Study 31014270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 0
Study 29522648 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide 0.6 mg
Number of subjects: 16
Study 29522648 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 10 mg or 20 mg
Number of subjects: 16
Study 29522648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27784322 — intervention group
Group type: EXPERIMENTAL
Intervention: T piece
Number of subjects: 17
Study 27784322 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV 0 and PEEP 0 cmH2O
Number of subjects: 17
Study 27784322 — intervention group
Group type: COMPARATOR
Intervention: PSV 7 and PEEP 7 cmH2O
Number of subjects: 17
Study 27784322 — intervention group
Group type: COMPARATOR
Intervention: PSV 0 and PEEP 7 cmH2O
Number of subjects: 17
Study 27784322 — intervention group
Group type: COMPARATOR
Intervention: PSV 7 and PEEP 0 cmH2O
Number of subjects: 17
Study 24222312 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy and hypofractionated external beam radiotherapy (EBRT) with long-term androgen deprivation therapy (ADT)
Number of subjects: 178
Study 22080619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline
Number of subjects: 64
Study 22080619 — intervention group
Group type: COMPARATOR
Intervention: Nebulized epinephrine
Number of subjects: 64
Study 22080619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 64
Study 19329101 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to Care Questionnaire (BCQ)
Number of subjects: 252
Study 17484092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg per day
Number of subjects: 844
Study 17484092 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg per day
Number of subjects: 844
Study 15139565 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 60
Study 15139565 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 60
Study 12270235 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Augmented Reality guidance system
Number of subjects: 50
Study 12270235 — intervention group
Group type: COMPARATOR
Intervention: Standard ultrasound-guided needle biopsy
Number of subjects: 50
Study 10049989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier introduction by 6 weeks
Number of subjects: 265
Study 10049989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier introduction before 2 weeks or before 6 weeks
Number of subjects: 265
Study 10049989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 265
Study 10049989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier introduction
Number of subjects: 265
Study 7572902 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 119
Study 7572902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily)
Number of subjects: 119
Study 7572902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 2178566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid (ASA) 1000 mg/day
Number of subjects: 66
Study 2178566 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 66
Study 2178566 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-salicylic acid (ASA)
Number of subjects: 66
Study 89499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg) 0.5 ml/kg within 48 hours after birth and 0.16 ml/kg every month for 6 months
Number of subjects: 41
Study 89499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 89499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIg)
Number of subjects: 41
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge + STOMP
Number of subjects: 517
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge alone
Number of subjects: 517
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMP alone
Number of subjects: 517
Study 31871245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 517
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMP
Number of subjects: 517
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher risk perception
Number of subjects: 517
Study 31871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental past opioid misuse
Number of subjects: 517
Study 30079635 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (1 mg bolus over 30 minutes followed by 2 μg/kg/h continuous infusion)
Number of subjects: 84
Study 30079635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline at the same volume and rate)
Number of subjects: 84
Study 30079635 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 84
Study 30079635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 27659394 — intervention group
Group type: EXPERIMENTAL
Intervention: Canady Hybrid Plasma Scalpel (CHPS)
Number of subjects: 244
Study 27659394 — intervention group
Group type: COMPARATOR
Intervention: Aquamantys Bipolar Sealer (BS)
Number of subjects: 244
Study 26323293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum for five days postoperatively
Number of subjects: 106
Study 26323293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 106
Study 23507223 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (4 cups per day)
Number of subjects: 35
Study 23507223 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water per day)
Number of subjects: 35
Study 23507223 — intervention group
Group type: COMPARATOR
Intervention: Control (4 cups water per day)
Number of subjects: 35
Study 23507223 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 35
Study 22166241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin in patients with gastric cancer
Number of subjects: 20
Study 22166241 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF in patients with gastric cancer
Number of subjects: 20
Study 22166241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin before surgery
Number of subjects: 20
Study 22166241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin after surgery
Number of subjects: 20
Study 19470058 — intervention group
Group type: EXPERIMENTAL
Intervention: Strip patch test (SPT)
Number of subjects: 30
Study 19470058 — intervention group
Group type: COMPARATOR
Intervention: Conventional patch test (PT)
Number of subjects: 30
Study 17052563 — intervention group
Group type: COMPARATOR
Intervention: i.v. ketamine 1 mg/kg
Number of subjects: 225
Study 17052563 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. ketamine 4 mg/kg
Number of subjects: 225
Study 10370910 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine (n = 7)
Number of subjects: 25
Study 10370910 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 25
Study 10370910 — intervention group
Group type: EXPERIMENTAL
Intervention: Budipine (open-label study, n = 9)
Number of subjects: 25
Study 8522684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary isosorbide dinitrate (2 mg)
Number of subjects: 36
Study 8522684 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 36
Study 8522684 — intervention group
Group type: COMPARATOR
Intervention: Post-isosorbide dinitrate measurements
Number of subjects: 36
Study 1862731 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123
Study 1862731 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 6303624 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 scintigraphy
Number of subjects: 91
Study 6303624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated blood pool imaging
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Thallium score less than 7
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Ejection fraction greater than 35%
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Concordant high-risk scintigrams
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Concordant low-risk studies
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Discordant results
Number of subjects: 91
Study 6303624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk thallium or blood pool scintigraphic results
Number of subjects: 91
Study 6303624 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium score of 7 or greater
Number of subjects: 91
Study 6303624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of thallium score, appearance of Q waves, and ejection fraction
Number of subjects: 91
Study 6303624 — intervention group
Group type: COMPARATOR
Intervention: Calculated chance of death less than 50%
Number of subjects: 91
Study 30215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Leniolisib (CDZ173), single oral dose of 400 mg
Number of subjects: 0
Study 29127604 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 4190
Study 29127604 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (ACRT)
Number of subjects: 4190
Study 29127604 — intervention group
Group type: COMPARATOR
Intervention: Postoperative observation (Control)
Number of subjects: 4190
Study 26823180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive journal club treatment arm
Number of subjects: 52
Study 26823180 — intervention group
Group type: COMPARATOR
Intervention: Self-study group
Number of subjects: 52
Study 25027335 — intervention group
Group type: COMPARATOR
Intervention: 3D‐CPA in high-grade CIN group
Number of subjects: 90